Sitagliptin alters bone composition in high fat fed mice

Sity Mansur, A Mieczkowska, PR Flatt, D Chappard, Nigel Irwin, G Mabilleau

Research output: Contribution to journalArticle

Abstract

Introduction: Type 2 diabetes mellitus (T2DM) is recognized as a significant risk factor for fragility of bone. Among the newer anti-diabetic agents, dipeptidyl peptidase-4 inhibitors (DPP4i) have been reported to decrease the occurrence of bone fractures although the reason is unclear. The main aim of this study was to evaluate the impact of sitagliptin treatment on tissue bone strength and
compositional parameters in the high fat fed mouse model.
Methods: Male NIH swiss mice were allowed free access to high fat diet (HFD) for 150 days to induce chronic hyperglycemia and insulin resistance. Sitagliptin was administered once daily for 3 weeks. High fat fed mice administered with saline were used as controls. Bone strength was assessed at the organ and tissue level by 3-point bending and nanoindentation, respectively. Bone microarchitecture was investigated by microcomputed tomography and bone composition was evaluated by Fourier transform infrared imaging and quantitative backscattered electron imaging.
Results: Administration of sitagliptin increased non-fasting insulin, improved glucose tolerance and increased insulin sensitivity. This was associated with clear ameliorations in bone strength at the organ and tissue level. No changes in trabecular or cortical microarchitectures were observed. On the other hand, higher values of Camean, Caturn, collagen maturity, mineral/matrix ratio, mineral maturity and crystal size index were evidenced after sitagliptin treatment. Correlation analysis significantly linked the modifications of bone strength to changes in bone compositional parameters.
Conclusions: These results bring new light on the mode of action of sitagliptin on bone physiology and demonstrate a benefit of DPP4i.
LanguageEnglish
Article numberxx
Pagesxx
JournalCalcified Tissue International
Volumexx
Issue numberxx
Publication statusAccepted/In press - 12 Dec 2018

Fingerprint

Fats
Bone and Bones
Dipeptidyl-Peptidase IV Inhibitors
Minerals
Insulin Resistance
Sitagliptin Phosphate
X-Ray Microtomography
Bone Fractures
High Fat Diet
Fourier Analysis
Hyperglycemia
Type 2 Diabetes Mellitus
Collagen
Electrons
Insulin
Light
Glucose

Keywords

  • sitagliptin
  • bone fragility
  • bone composition
  • type 2 diabetes

Cite this

Mansur, S., Mieczkowska, A., Flatt, PR., Chappard, D., Irwin, N., & Mabilleau, G. (Accepted/In press). Sitagliptin alters bone composition in high fat fed mice. Calcified Tissue International, xx(xx), xx. [xx].
Mansur, Sity ; Mieczkowska, A ; Flatt, PR ; Chappard, D ; Irwin, Nigel ; Mabilleau, G. / Sitagliptin alters bone composition in high fat fed mice. In: Calcified Tissue International. 2018 ; Vol. xx, No. xx. pp. xx.
@article{20cb32beb5694f9fb3938f474530d22f,
title = "Sitagliptin alters bone composition in high fat fed mice",
abstract = "Introduction: Type 2 diabetes mellitus (T2DM) is recognized as a significant risk factor for fragility of bone. Among the newer anti-diabetic agents, dipeptidyl peptidase-4 inhibitors (DPP4i) have been reported to decrease the occurrence of bone fractures although the reason is unclear. The main aim of this study was to evaluate the impact of sitagliptin treatment on tissue bone strength andcompositional parameters in the high fat fed mouse model.Methods: Male NIH swiss mice were allowed free access to high fat diet (HFD) for 150 days to induce chronic hyperglycemia and insulin resistance. Sitagliptin was administered once daily for 3 weeks. High fat fed mice administered with saline were used as controls. Bone strength was assessed at the organ and tissue level by 3-point bending and nanoindentation, respectively. Bone microarchitecture was investigated by microcomputed tomography and bone composition was evaluated by Fourier transform infrared imaging and quantitative backscattered electron imaging.Results: Administration of sitagliptin increased non-fasting insulin, improved glucose tolerance and increased insulin sensitivity. This was associated with clear ameliorations in bone strength at the organ and tissue level. No changes in trabecular or cortical microarchitectures were observed. On the other hand, higher values of Camean, Caturn, collagen maturity, mineral/matrix ratio, mineral maturity and crystal size index were evidenced after sitagliptin treatment. Correlation analysis significantly linked the modifications of bone strength to changes in bone compositional parameters.Conclusions: These results bring new light on the mode of action of sitagliptin on bone physiology and demonstrate a benefit of DPP4i.",
keywords = "sitagliptin, bone fragility, bone composition, type 2 diabetes",
author = "Sity Mansur and A Mieczkowska and PR Flatt and D Chappard and Nigel Irwin and G Mabilleau",
year = "2018",
month = "12",
day = "12",
language = "English",
volume = "xx",
pages = "xx",
journal = "Calcified Tissue International",
issn = "0171-967X",
number = "xx",

}

Mansur, S, Mieczkowska, A, Flatt, PR, Chappard, D, Irwin, N & Mabilleau, G 2018, 'Sitagliptin alters bone composition in high fat fed mice', Calcified Tissue International, vol. xx, no. xx, xx, pp. xx.

Sitagliptin alters bone composition in high fat fed mice. / Mansur, Sity; Mieczkowska, A; Flatt, PR; Chappard, D; Irwin, Nigel; Mabilleau, G.

In: Calcified Tissue International, Vol. xx, No. xx, xx, 12.12.2018, p. xx.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sitagliptin alters bone composition in high fat fed mice

AU - Mansur, Sity

AU - Mieczkowska, A

AU - Flatt, PR

AU - Chappard, D

AU - Irwin, Nigel

AU - Mabilleau, G

PY - 2018/12/12

Y1 - 2018/12/12

N2 - Introduction: Type 2 diabetes mellitus (T2DM) is recognized as a significant risk factor for fragility of bone. Among the newer anti-diabetic agents, dipeptidyl peptidase-4 inhibitors (DPP4i) have been reported to decrease the occurrence of bone fractures although the reason is unclear. The main aim of this study was to evaluate the impact of sitagliptin treatment on tissue bone strength andcompositional parameters in the high fat fed mouse model.Methods: Male NIH swiss mice were allowed free access to high fat diet (HFD) for 150 days to induce chronic hyperglycemia and insulin resistance. Sitagliptin was administered once daily for 3 weeks. High fat fed mice administered with saline were used as controls. Bone strength was assessed at the organ and tissue level by 3-point bending and nanoindentation, respectively. Bone microarchitecture was investigated by microcomputed tomography and bone composition was evaluated by Fourier transform infrared imaging and quantitative backscattered electron imaging.Results: Administration of sitagliptin increased non-fasting insulin, improved glucose tolerance and increased insulin sensitivity. This was associated with clear ameliorations in bone strength at the organ and tissue level. No changes in trabecular or cortical microarchitectures were observed. On the other hand, higher values of Camean, Caturn, collagen maturity, mineral/matrix ratio, mineral maturity and crystal size index were evidenced after sitagliptin treatment. Correlation analysis significantly linked the modifications of bone strength to changes in bone compositional parameters.Conclusions: These results bring new light on the mode of action of sitagliptin on bone physiology and demonstrate a benefit of DPP4i.

AB - Introduction: Type 2 diabetes mellitus (T2DM) is recognized as a significant risk factor for fragility of bone. Among the newer anti-diabetic agents, dipeptidyl peptidase-4 inhibitors (DPP4i) have been reported to decrease the occurrence of bone fractures although the reason is unclear. The main aim of this study was to evaluate the impact of sitagliptin treatment on tissue bone strength andcompositional parameters in the high fat fed mouse model.Methods: Male NIH swiss mice were allowed free access to high fat diet (HFD) for 150 days to induce chronic hyperglycemia and insulin resistance. Sitagliptin was administered once daily for 3 weeks. High fat fed mice administered with saline were used as controls. Bone strength was assessed at the organ and tissue level by 3-point bending and nanoindentation, respectively. Bone microarchitecture was investigated by microcomputed tomography and bone composition was evaluated by Fourier transform infrared imaging and quantitative backscattered electron imaging.Results: Administration of sitagliptin increased non-fasting insulin, improved glucose tolerance and increased insulin sensitivity. This was associated with clear ameliorations in bone strength at the organ and tissue level. No changes in trabecular or cortical microarchitectures were observed. On the other hand, higher values of Camean, Caturn, collagen maturity, mineral/matrix ratio, mineral maturity and crystal size index were evidenced after sitagliptin treatment. Correlation analysis significantly linked the modifications of bone strength to changes in bone compositional parameters.Conclusions: These results bring new light on the mode of action of sitagliptin on bone physiology and demonstrate a benefit of DPP4i.

KW - sitagliptin

KW - bone fragility

KW - bone composition

KW - type 2 diabetes

M3 - Article

VL - xx

SP - xx

JO - Calcified Tissue International

T2 - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - xx

M1 - xx

ER -

Mansur S, Mieczkowska A, Flatt PR, Chappard D, Irwin N, Mabilleau G. Sitagliptin alters bone composition in high fat fed mice. Calcified Tissue International. 2018 Dec 12;xx(xx):xx. xx.